Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Chamberlain

Showing results (1-10 of 44) with videos related to

Pageof 5
Sort By:
Drug Discovery Today|September 24, 2004
Biogenerics: Europe takes another step forward while the FDA dives for coverPaul Chamberlain
Bioanalysis|February 22, 2013
Assessing immunogenicity of biosimilar therapeutic monoclonal antibodies: regulatory and bioanalytical considerationsPaul Chamberlain
New Biotechnology|April 9, 2011
Pre-clinical strategies and safety issues in developing therapeutic monoclonal antibodiesPaul Chamberlain
Bioanalysis|February 16, 2019
Effective presentation of immunogenicity risk assessments and related data in regulatory dossiersPaul Chamberlain
Lancet (London, England)|April 27, 2005
Death after withdrawal of nutrition and hydrationPaul Chamberlain
Journal of Immunotoxicology|October 30, 2008
Immunogenicity for biologics: do we have the right tools to assess risk?Paul Chamberlain
The AAPS Journal|April 16, 2020
Immunogenicity Risk Assessment for an Engineered Human Cytokine Analogue Expressed in Different Cell SubstratesPaul Chamberlain, Bonita Rup
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|January 14, 2016
Controversies in Establishing Biosimilarity: Extrapolation of Indications and Global Labeling PracticesHans C Ebbers, Paul Chamberlain
BMJ (Clinical Research Ed.)|July 19, 2003
Terminology for our times: others will have similar examplesPatricia A Boyd, Paul Chamberlain
Ophthalmic & Physiological Optics : the Journal of the British College of Ophthalmic Opticians (Optometrists)|August 17, 2021
Author's replyPaul Chamberlain, Mark A Bullimore
Pageof 5

Showing results (1-10 of 44) with videos related to

Sort By:
Pageof 5
Drug Discovery Today|September 24, 2004
Biogenerics: Europe takes another step forward while the FDA dives for coverPaul Chamberlain
Bioanalysis|February 22, 2013
Assessing immunogenicity of biosimilar therapeutic monoclonal antibodies: regulatory and bioanalytical considerationsPaul Chamberlain
New Biotechnology|April 9, 2011
Pre-clinical strategies and safety issues in developing therapeutic monoclonal antibodiesPaul Chamberlain
Bioanalysis|February 16, 2019
Effective presentation of immunogenicity risk assessments and related data in regulatory dossiersPaul Chamberlain
Lancet (London, England)|April 27, 2005
Death after withdrawal of nutrition and hydrationPaul Chamberlain
Journal of Immunotoxicology|October 30, 2008
Immunogenicity for biologics: do we have the right tools to assess risk?Paul Chamberlain
The AAPS Journal|April 16, 2020
Immunogenicity Risk Assessment for an Engineered Human Cytokine Analogue Expressed in Different Cell SubstratesPaul Chamberlain, Bonita Rup
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|January 14, 2016
Controversies in Establishing Biosimilarity: Extrapolation of Indications and Global Labeling PracticesHans C Ebbers, Paul Chamberlain
BMJ (Clinical Research Ed.)|July 19, 2003
Terminology for our times: others will have similar examplesPatricia A Boyd, Paul Chamberlain
Ophthalmic & Physiological Optics : the Journal of the British College of Ophthalmic Opticians (Optometrists)|August 17, 2021
Author's replyPaul Chamberlain, Mark A Bullimore
Pageof 5